Abstract：
BACKGROUND: Long non-coding RNA (lncRNA) is a class of single-stranded RNA biomolecules involving over 200 nucleotides and does not encode proteins. Research on lncRNA has become a hot spot for the past few years. DNM3OS (Dynamin 3 Opposite Strand), which has been clearly identified as a regulatory lncRNA, exerts an integral role in the pathophysiology of multiple human diseases.
OBJECTIVE: The current review study summarizes the pathogenic mechanism of DNM3OS in various pathophysiological processes, aiming to reveal its important value as a therapeutic drug target for related human diseases and provide a new way for targeted therapy.
METHODS: Through systematic retrieval and in-depth study of relevant articles in PubMed, this article analyzes and summarizes the pathogenic roles and molecular mechanisms in pathophysiological processes of long non-coding RNA DNM3OS.
RESULTS: DNM3OS exerts an important regulatory role in the occurrence and development of bone diseases, neoplastic diseases, fibrotic diseases, inflammatory diseases, and many other diseases.
CONCLUSIONS: DNM3OS is a potential new biomarker and therapeutic target for the treatment of a series of diseases, consisting of bone diseases, neoplastic diseases, fibrotic diseases, and inflammatory diseases.
OBJECTIVE: The current review study summarizes the pathogenic mechanism of DNM3OS in various pathophysiological processes, aiming to reveal its important value as a therapeutic drug target for related human diseases and provide a new way for targeted therapy.
METHODS: Through systematic retrieval and in-depth study of relevant articles in PubMed, this article analyzes and summarizes the pathogenic roles and molecular mechanisms in pathophysiological processes of long non-coding RNA DNM3OS.
RESULTS: DNM3OS exerts an important regulatory role in the occurrence and development of bone diseases, neoplastic diseases, fibrotic diseases, inflammatory diseases, and many other diseases.
CONCLUSIONS: DNM3OS is a potential new biomarker and therapeutic target for the treatment of a series of diseases, consisting of bone diseases, neoplastic diseases, fibrotic diseases, and inflammatory diseases.
摘要：
背景：长非编码RNA（lncRNA）是一类涉及200多个核苷酸的单链RNA生物分子，不编码蛋白质。lncRNA的研究已成为过去几年的热点。DNM3OS(Dynamin3对岸链),已被明确鉴定为调节性lncRNA，在多种人类疾病的病理生理学中起着不可或缺的作用。
目的：本综述综述了DNM3OS在各种病理生理过程中的致病机制。旨在揭示其作为人类相关疾病治疗药物靶点的重要价值,为靶向治疗提供新的途径。
方法：通过对PubMed中相关文章的系统检索和深入研究，本文就长链非编码RNADNM3OS在病理生理过程中的致病作用和分子机制进行分析和总结。
结果：DNM3OS在骨病的发生发展过程中发挥着重要的调节作用，肿瘤疾病，纤维化疾病,炎症性疾病，和许多其他疾病。
结论：DNM3OS是治疗一系列疾病的潜在新生物标志物和治疗靶点，由骨骼疾病组成，肿瘤疾病，纤维化疾病,和炎症性疾病。
目的：本综述综述了DNM3OS在各种病理生理过程中的致病机制。旨在揭示其作为人类相关疾病治疗药物靶点的重要价值,为靶向治疗提供新的途径。
方法：通过对PubMed中相关文章的系统检索和深入研究，本文就长链非编码RNADNM3OS在病理生理过程中的致病作用和分子机制进行分析和总结。
结果：DNM3OS在骨病的发生发展过程中发挥着重要的调节作用，肿瘤疾病，纤维化疾病,炎症性疾病，和许多其他疾病。
结论：DNM3OS是治疗一系列疾病的潜在新生物标志物和治疗靶点，由骨骼疾病组成，肿瘤疾病，纤维化疾病,和炎症性疾病。
